Drug & intervention

cemiplimab

RxCUI 2058826

Clinical trials50
Recruiting19
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 LevelsNCT07360743 · 2026-08-21
RECRUITING
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%NCT07020065 · 2026-04-10
RECRUITING
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02
RECRUITING
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior ChemotherapyNCT06931717 · 2026-01-12
RECRUITING
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304 · 2025-12-08
RECRUITING
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17
RECRUITING
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · 2025-11-07
RECRUITING
Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung CancerNCT06743581 · 2025-08-19
RECRUITING
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung CancerNCT06865339 · 2025-08-07
RECRUITING
PALACE: Cemiplimab Trial According to ctDNA LevelsNCT06917573 · 2025-07-29
RECRUITING
A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPCNCT06826768 · 2025-07-09
RECRUITING
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLCNCT06623656 · 2025-02-21
RECRUITING
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsNCT06171750 · 2024-01-19
RECRUITING
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsNCT06090266 · 2023-10-24
RECRUITING
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.NCT06022029 · 2023-10-13
RECRUITING
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319 · 2022-10-26
RECRUITING
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain MetsNCT05317858 · 2022-08-12
RECRUITING
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657 · 2019-08-12
RECRUITING
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerNCT01042379 · 2010-03-01
RECRUITING
Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1NCT07450183 · 2027-01-01
NOT_YET_RECRUITING
Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung CancerNCT07720167 · 2026-11-01
NOT_YET_RECRUITING
Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialNCT07746388 · 2026-09-01
NOT_YET_RECRUITING
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 TrialNCT07274384 · 2026-01-01
NOT_YET_RECRUITING
TOP 2301: Neoadjuvant Chemo for NSCLCNCT06385262 · 2025-03-17
SUSPENDED
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCNCT06219317 · 2025-01-14
ACTIVE_NOT_RECRUITING
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)NCT06465329 · 2024-11-18
ACTIVE_NOT_RECRUITING
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)NCT06162572 · 2024-08-07
ACTIVE_NOT_RECRUITING
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung CancerNCT06532149 · 2024-08-05
UNKNOWN
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With SurgeryNCT06161441 · 2024-07-16
ACTIVE_NOT_RECRUITING
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesNCT06052852 · 2023-10-11
TERMINATED
Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)NCT05882734 · 2023-09-13
COMPLETED
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.NCT05704634 · 2023-08-18
ACTIVE_NOT_RECRUITING
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerNCT05800015 · 2023-08-08
ACTIVE_NOT_RECRUITING
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767 · 2023-06-30
ACTIVE_NOT_RECRUITING
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsNCT05864144 · 2023-05-31
COMPLETED
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)NCT05557591 · 2023-04-21
ACTIVE_NOT_RECRUITING
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCNCT05401786 · 2023-01-03
ACTIVE_NOT_RECRUITING
THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944 · 2022-06-08
ACTIVE_NOT_RECRUITING
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate CancerNCT04989946 · 2021-12-16
ACTIVE_NOT_RECRUITING
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerNCT04916002 · 2021-11-30
TERMINATED

Leading sponsors

Regeneron Pharmaceuticals13Intergroupe Francophone de Cancerologie Thoracique2M.D. Anderson Cancer Center2Maia Biotechnology2OncoResponse, Inc.2Ankyra Therapeutics, Inc1BioNTech SE1Bolt Biotherapeutics, Inc.1Centre hospitalier de l'Université de Montréal (CHUM)1Duke University1EMD Serono Research & Development Institute, Inc.1ETOP IBCSG Partners Foundation1European Organisation for Research and Treatment of Cancer - EORTC1Fondazione Policlinico Universitario Agostino Gemelli IRCCS1Fundación GECP1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.